ReviewJournal of neural transmission (Vienna, Austria : 1996)2008
Neuroproteomics as a promising tool in Parkinson's disease research.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Transcriptomics and Proteomics Approach for the Identification of Altered Blood microRNAs and Plasma Proteins in Parkinson's Disease.Cellular and molecular neurobiology · 2023Article
- Identification of Altered Blood MicroRNAs and Plasma Proteins in a Rat Model of Parkinson's Disease.Molecular neurobiology · 2022Article
- Article
- Proteomics and bioinformatics approaches for the identification of plasma biomarkers to detect Parkinson's disease.Experimental and therapeutic medicine · 2019Article
- Proteomics in Human Parkinson's Disease: Present Scenario and Future Directions.Cellular and molecular neurobiology · 2019Review
- Protein Co-Aggregation Related to Amyloids: Methods of Investigation, Diversity, and Classification.International journal of molecular sciences · 2018Review
- Clinical implications from proteomic studies in neurodegenerative diseases: lessons from mitochondrial proteins.Expert review of proteomics · 2016Review
- Tumor Necrosis Factor-Associated Protein 1 (TRAP1) is Released from the Mitochondria Following 6-hydroxydopamine Treatment.Experimental neurobiology · 2014Article
- Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis.Molecular neurobiology · 2012Review
- Parkinson's disease mouse models in translational research.Mammalian genome : official journal of the International Mammalian Genome Society · 2011Review
- Nuclear translocation of anamorsin during drug-induced dopaminergic neurodegeneration in culture and in rat brain.Journal of neural transmission (Vienna, Austria : 1996) · 2011Article
- ENU mutagenesis screen to establish motor phenotypes in wild-type mice and modifiers of a pre-existing motor phenotype in tau mutant mice.Journal of biomedicine & biotechnology · 2011Review
- Discovery and verification of osteopontin and Beta-2-microglobulin as promising markers for staging human African trypanosomiasis.Molecular & cellular proteomics : MCP · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Despite the vast number of studies on Parkinson's disease (PD), its effective diagnosis and treatment remains unsatisfactory. Hence, the relentless search for an optimal cure continues. The emergence of neuroproteomics, with its sophisticated techniques and non-biased ability to quantify proteins, provides a methodology with which to study the changes in neurons that are associated with neurodegeneration. Neuroproteomics is an emerging tool to establish disease-associated protein profiles, while also generating a greater understanding as to how these proteins interact and undergo post-translational modifications. Furthermore, due to the advances made in bioinformatics, insight is created concerning their functional characteristics. In this review, we first summarize the most prominent proteomics techniques and then discuss the major advances in the fast-growing field of neuroproteomics in PD. Ultimately, it is hoped that the application of this technology will lead towards a presymptomatic diagnosis of PD, and the identification of risk factors and new therapeutic targets at which pharmacological intervention can be aimed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.